Gilead Sciences, Inc. news

   Watch this stock
Showing stories 11 - 20 of about 127   

Articles published

GILD 56.47 +0.73 (1.31%)
price chart
GILEAD SCIENCES, INC. : Gilead Sciences to Release First Quarter 2013 ...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2013 financial results will be released on Thursday, May 2, at 4:05 p.m.
Gilead Sciences, Inc. (GILD) Leading the Charge in Hepatitis C Space with ...  The Wall Street Transcript (blog)
Stocks In News (HomeAway, Synergy Pharmaceuticals Inc, IAMGOLD ...  Mesh Press (press release)
Related articles »  
Gilead Sciences, Inc.(NASDAQ:GILD) Hits New high On First Quarter Results
The market celebrated the first quarter results of Gilead Sciences, Inc.(NASDAQ:GILD) by sending the shares of the company to an all-time high on Friday.
Investors Buzz: Gilead Sciences, Inc.(NASDAQ:GILD), Philip Morris ...  SBWire (press release)
Related articles »  
FDA rejects 2 HIV drugs from Gilead Sciences
Gilead Sciences Inc. said Monday that the Food and Drug Administration rejected two marketing applications for HIV treatments, citing quality control problems at the company's manufacturing facilities.
FDA rejects two Gilead HIV drugs as standalone products  Reuters
Related articles »  
Is Gilead Sciences, Inc. (GILD) Still A Buy?
Gilead Sciences, Inc. (NASDAQ:GILD) reported a relatively rare earnings miss in the first quarter on May 2. The biotech announced earnings of $0.48 per share while analysts were expecting $0.50 per share.
Gilead Sciences Inc. (NASDAQ:GILD), Express Scripts Holding Company ...
New York, NY -- (SBWIRE) -- 05/07/2013 -- Growing Stock Report expands its NASDAQ Decliners Weekly Watch List adding Gilead Sciences Inc. (NASDAQ:GILD), Express Scripts Holding Company (NASDAQ:ESRX), and Life Technologies Corporation ...
Related articles »  
Biotech Most Active & Overbought stocks, Peregrine Pharmaceuticals, Gilead ...
Gilead Sciences, Inc. (NASDAQ:GILD) recently disclosed in its Global Healthcare Conference that the company has launched its Stribild tablet in the United States back in August of last year and since then the company recorded under 100 million in terms ...
Related articles »  
GILEAD SCIENCES, INC. : Data from Phase 3 Studies of Gilead's Sofosbuvir for ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that detailed results from four Phase 3 clinical trials (NEUTRINO, FISSION, POSITRON and FUSION) evaluating sofosbuvir, the company's investigational once-daily nucleotide NS5B inhibitor for the ...
AbbVie says drug cocktail wipes out hepatitis C in 8 weeks  Chicago Tribune
AbbVie hepatitis C drugs knock out virus at eight weeks  Reuters India
Related articles »  
Monster Beverage Becomes #26 Most Shorted Nasdaq 100 Component ...
In our new rank based on the most recent short interest data from NASDAQ, Monster Beverage Corp (NASD: MNST) has taken over the position of #26 most shorted Nasdaq 100 component, from Gilead Sciences, Inc. (NASD: GILD) which is now in the # spot.
Related articles »  
Active Buzzers: Citigroup Inc, Boston Scientific Corporation, Morgan Stanley ...
Apr 22, 2013 (ACCESSWIRE-TNW via COMTEX) -- NEW YORK, April 22, 2013 -Bestdarnpennystocks.com, one of the leaders in providing investment alerts on U.S.
Gilead Sciences Receives Overweight Rating from JPMorgan Chase (GILD)  Mideast Time
Gilead Sciences PT Raised to $65.00 at Morgan Stanley (GILD)  The Utah People's Post
Related articles »  
Trace Insider Trading in Intel, Pfizer, Gilead Sciences, General Electric ...
Gilead Sciences, Inc. (NASDAQ: GILD): By the end of last trading session, Gilead Sciences (NASDAQ: GILD) dropped US$0.72 (or 1.31%) to US$54.43 with about 13.33 million shares exchanged hands for the session, compared to its average volume of ...
Gilead Sciences Receives Neutral Rating from Zacks (GILD)  Mideast Time
Gilead Sciences Given Outperform Rating at BMO Capital Markets (GILD)  Zolmax
Related articles »